REGULATED PRESS RELEASE published on 08/28/2025 at 07:00, 10 months 11 days ago Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial Biophytis receives EMA and Belgian regulatory approval for Phase 3 sarcopenia clinical trial, marking a significant milestone in developing therapies for muscle loss in aging individuals Biophytis Sarcopenia Phase 3 EMA Belgian Regulatory Approval
PRESS RELEASE published on 08/28/2025 at 07:00, 10 months 11 days ago Exail strengthens its position in the surface drone sector with the first sale of a new long-range DriX drone model Exail Technologies announces the sale of the DriX H-9, expanding its autonomous surface drone solutions for civil and defense markets. The H-9 offers enhanced capabilities for maritime missions Exail Technologies Defense Applications Autonomous Drones DriX H-9 Maritime Missions
PRESS RELEASE published on 08/28/2025 at 06:59, 10 months 11 days ago Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial Biophytis receives EMA and Belgian regulatory approval for Phase 3 sarcopenia clinical trial, enabling patient enrolment in Belgium and collaboration with European centers Biophytis Sarcopenia Phase 3 EMA Approval Belgian Regulatory Approval
PRESS RELEASE published on 08/28/2025 at 06:57, 10 months 11 days ago EQS-Adhoc: PIERER Mobility AG: Results for the first half of 2025 PIERER Mobility AG announces successful completion of restructuring proceedings in H1 2025, with positive results and strategic initiatives for motorcycle and bicycle segments PIERER Mobility AG Results Motorcycle Restructuring Proceedings Bicycle
PRESS RELEASE published on 08/28/2025 at 06:50, 10 months 11 days ago Daldrup & Söhne AG increases EBIT margin and specifies EBIT forecast Daldrup & Söhne AG increases EBIT margin to 12.6% and revises 2025 EBIT forecast. Order backlog reaches EUR 140 million. Detailed 2025 outlook provided Financial Performance EBIT Margin Order Backlog Forecast Daldrup & Söhne
PRESS RELEASE published on 08/28/2025 at 06:38, 10 months 11 days ago Ad hoc announcement pursuant to Art. 53 LR: Jungfraubahn Holding AG - The Jungfrau Railway Group achieves record profit in the first half of the year Jungfraubahn Holding AG reports record profit in the first half of 2025, driven by increased transport income. New CEO and sustainability efforts highlighted Sustainability Jungfraubahn Holding AG Record Profit New CEO Transport Income
PRESS RELEASE published on 08/28/2025 at 06:30, 10 months 11 days ago Helvetica Swiss Commercial Fund impresses in the first half of 2025 with strong net income, performance above the benchmark and successful fund merger Helvetica Swiss Commercial Fund achieves strong net income and performance above benchmark in first half of 2025 with a successful fund merger. Details in HSC Fund's 2025 Half-Year Report Net Income Helvetica Swiss Commercial Fund Fund Merger 2025 Financial Results Benchmark Performance
PRESS RELEASE published on 08/28/2025 at 06:30, 10 months 11 days ago Helvetica Swiss Living Fund impresses in the first half of 2025 with significantly higher total profit, increased net income per unit and strong return on investment Helvetica Swiss Living Fund reports strong financial performance in the first half of 2025, with increased net income per unit and 2.94% return on investment Financial Performance Net Income HSL Fund Helvetica Swiss Living Fund Return On Investment
PRESS RELEASE published on 08/28/2025 at 06:30, 10 months 11 days ago Pleasing half-year results for Cham Swiss Properties Cham Swiss Properties AG reports pleasing half-year results, with net income from revaluation boosting consolidated profit to CHF 144.0 million and equity ratio at 61.1%. Operating result excluding revaluation is CHF 39.0 million Half-year Results Operating Result Equity Ratio Revaluation Cham Swiss Properties
PRESS RELEASE published on 08/28/2025 at 03:50, 10 months 11 days ago EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx Heidelberg Pharma's partner Telix Pharmaceuticals faces delays in TLX250-CDx FDA approval. USD 70 million payment from HealthCare Royalty postponed. Current cash reach until Q1 2026 FDA Approval Heidelberg Pharma HealthCare Royalty Telix Pharmaceuticals TLX250-CDx
Published on 07/08/2026 at 15:25, 5 hours 57 minutes ago Rockhaven Announces Granting of Incentive Stock Options
Published on 07/08/2026 at 15:00, 6 hours 22 minutes ago Karbon-X Announces Strategic Partnership to Evaluate Kenya BioHub Initiative
Published on 07/08/2026 at 15:00, 6 hours 22 minutes ago GameSquare's Stream Hatchet Publishes Esports Live Streaming Trends Report
Published on 07/08/2026 at 14:30, 6 hours 52 minutes ago Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
Published on 07/08/2026 at 21:00, 22 minutes ago Legendary Entertainment and Warner Bros. Pictures Unveil Dune: Part Three Trailer and Behind-the-Scenes Images Showcasing Abu Dhabi as Arrakis
Published on 07/08/2026 at 19:42, 1 hour 39 minutes ago EQS-Adhoc: SMAG Mobile Antenna Masts AG sets final offer price for initial public offering (IPO) at EUR 46 per share
Published on 07/08/2026 at 18:45, 2 hours 37 minutes ago EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma publishes preliminary Q3 key figures and raises 2026 revenue and earnings guidance
Published on 07/08/2026 at 18:00, 3 hours 22 minutes ago €464 MILLION OF NEW FINANCING TO SUPPORT FREY'S GROWTH
Published on 07/08/2026 at 17:45, 3 hours 37 minutes ago Half-year liquidity contract statement of ALTEN SA as at 30 June 2026
Published on 07/08/2026 at 17:40, 3 hours 42 minutes ago Report on share repurchases from 1 to 7 July 2026
Published on 07/08/2026 at 11:15, 10 hours 7 minutes ago Half-year statement of the liquidity contract H1 2026